Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+AML ineligible for intensive chemotherapy
- Resource Type
- Article
- Source
- Blood; October 2022, Vol. 140 Issue: 17 p1845-1857, 13p
- Subject
- Language
- ISSN
- 00064971; 15280020